

Anna M Varghese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/203599/publications.pdf>

Version: 2024-02-01

71
papers

8,266
citations

109321

35
h-index

91884

69
g-index

71
all docs

71
docs citations

71
times ranked

14705
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Characterization of Peritoneal Mesotheliomas. <i>Journal of Thoracic Oncology</i> , 2022, 17, 455-460.	1.1	24
2	Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. <i>Lung Cancer</i> , 2022, 165, 1-9.	2.0	15
3	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	3.7	12
4	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
5	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2200-2208.	7.0	51
6	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1194-1202.	6.3	35
7	Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. <i>Investigational New Drugs</i> , 2021, 39, 1081-1088.	2.6	10
8	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 911-919.	1.6	34
9	Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity. <i>Pancreatology</i> , 2021, 21, 599-605.	1.1	4
10	Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. <i>Annals of Surgery</i> , 2021, 274, 894-901.	4.2	15
11	Treatment patterns and survival in patients with early-onset pancreatic cancer. <i>Cancer</i> , 2021, 127, 3566-3578.	4.1	20
12	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763.	9.4	222
13	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	6.3	66
14	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	1.6	83
15	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. <i>Cancer</i> , 2021, 127, 4393-4402.	4.1	24
16	The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. <i>The Lancet Digital Health</i> , 2021, 3, e565-e576.	12.3	23
17	V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. <i>Modern Pathology</i> , 2020, 33, 303-311.	5.5	65
18	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. <i>JAMA Oncology</i> , 2020, 6, 84.	7.1	66

#	ARTICLE	IF	CITATIONS
19	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 60.	7.1	112
20	Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 655-660.	1.1	25
21	Insertion of an Alu-like element in <i>MLH1</i> intron 7 as a novel cause of Lynch syndrome. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1523.	1.2	4
22	Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1871-1879.	1.1	24
23	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2020, 126, 3939-3949.	4.1	44
24	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	7.0	118
25	Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. <i>Modern Pathology</i> , 2020, 33, 1822-1831.	5.5	40
26	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. <i>Clinical Cancer Research</i> , 2020, 26, 3239-3247.	7.0	135
27	Practical Application of Real-World Evidence in Developing Cancer Therapies. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-2.	2.1	6
28	Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1042.	2.8	10
29	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz015.	2.9	16
30	Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. <i>Cancer Treatment Reviews</i> , 2019, 75, 27-38.	7.7	32
31	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 286-295.	1.6	397
32	“A Tool, Not a Crutch” Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering. <i>Journal of Oncology Practice</i> , 2019, 15, e277-e288.	2.5	28
33	Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. <i>Cancer</i> , 2019, 125, 1441-1448.	4.1	28
34	FOLFACIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e39-e52.	2.3	21
35	Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2018, 17, 121-128.	2.3	21
36	A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3253-3262.	7.0	71

#	ARTICLE	IF	CITATIONS
37	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018, 24, 1326-1336.	7.0	281
38	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018, 33, 125-136.e3.	16.8	589
39	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2018, 4, e180071.	7.1	404
40	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	1.1	85
41	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565.	9.4	422
42	Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. <i>BMC Cancer</i> , 2018, 18, 693.	2.6	68
43	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
44	Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 61-69.	0.8	19
45	Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 993-1000.	1.1	53
46	CAR T cell therapy for pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 63-74.	1.7	69
47	Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. <i>Immunotherapy</i> , 2017, 9, 913-927.	2.0	44
48	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017, 23, 6094-6100.	7.0	161
49	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017, 123, 1134-1143.	4.1	43
50	Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. <i>Oncotarget</i> , 2017, 8, 77872-77882.	1.8	31
51	Chimeric antigen receptor (CAR) T and other T cell strategies for pancreas adenocarcinoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 66-66.	1.2	10
52	Current management and future directions in metastatic pancreatic adenocarcinoma. <i>Cancer</i> , 2016, 122, 3765-3775.	4.1	18
53	A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 23-30.	2.0	57
54	Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2761-2768.	1.6	154

#	ARTICLE	IF	CITATIONS
55	Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2874-2884.	7.0	103
56	Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 249-255.	1.1	53
57	Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. <i>PLoS ONE</i> , 2016, 11, e0146063.	2.5	17
58	Chemotherapy for Stage II Colon Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2015, 28, 256-261.	1.1	57
59	Localized malignant pleural mesothelioma with renal metastasis. <i>Oxford Medical Case Reports</i> , 2015, 2015, 170-172.	0.4	11
60	Genomic Profiling of Cancers of Unknown Primary Site. <i>JAMA Oncology</i> , 2015, 1, 541.	7.1	1
61	Tumor of Unknown Primary Site. , 2015, , 162-167.		0
62	Advancing clinical oncology through genome biology and technology. <i>Genome Biology</i> , 2014, 15, 427.	8.8	9
63	Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 394-401.	0.8	55
64	Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes. <i>Journal of Thoracic Oncology</i> , 2014, 9, 892-896.	1.1	106
65	<i>ALK</i> Rearrangements Are Mutually Exclusive with Mutations in <i>EGFR</i> or <i>KRAS</i> : An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4273-4281.	7.0	521
66	Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1430-1433.	1.1	81
67	Lungs Don't Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2013, 8, 123-125.	1.1	33
68	Response to Erlotinib in Patients with <i>EGFR</i> Mutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2535-2540.	4.1	46
69	Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 487-90.	1.7	9
70	Novel Therapies in Phase II and III Trials for Malignant Pleural Mesothelioma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 42-47.	4.9	22
71	The Evolution of Multimodality Therapy for Malignant Pleural Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2011, 12, 163-172.	3.0	37